暴发性1型糖尿病1例

王 意,李浩言,甘 泉,王宏宇,徐 春

武警医学 ›› 2017, Vol. 28 ›› Issue (1) : 83-85.

PDF(1018 KB)
PDF(1018 KB)
武警医学 ›› 2017, Vol. 28 ›› Issue (1) : 83-85.
临床经验总结

暴发性1型糖尿病1例

  • 王 意1,李浩言1,甘 泉2,王宏宇1,徐 春1
作者信息 +
文章历史 +

摘要

暴发性1型糖尿病(fulminant type 1 diabetes mellitus,FT1D)是日本学者Imagawa等[1]于2000年提出的1 型糖尿病的新亚型,根据1999年WHO糖尿病分型标准,暂归为特发性1型糖尿病( idiopathic type 1 diabetes,1B 型)。FT1D起病急骤,且极易误诊,现分析本院收治的1例FT1D患者的临床资料,以提高对该病的认识和诊治水平。

关键词

暴发性1型糖尿病 / 病因 / 治疗 / 预后

引用本文

导出引用
王 意,李浩言,甘 泉,王宏宇,徐 春. 暴发性1型糖尿病1例[J]. 武警医学. 2017, 28(1): 83-85
中图分类号: R781.6   

参考文献

[1] Imagawa A,Hanafusa T,Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies.Osaka IDDM Study Group[J].N Engl J Med,2000,342(5):301-307.
[2] Imagawa A,Hanafusa T,Uchigata Y,et al.Fulminant type 1 diabetes: a nationwide survey in Japan[J].Diabetes Care,2003,26(8):2345-2352.
[3] Kim N H, Kim H Y, Seo J A, et al.A pooled analysis of 29 patients with fulminant type 1 diabetes in Korea: a comparison with a nationwide survey in Japan[J].Diabetes Res Clin Pract,2009,86(3):e43-45.
[4] Cho Y M,Kim J T,Ko K S,et al.Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes[J]. Diabetologia ,2007,50(11):2276-2279.
[5] 张 弛,周智广,张冬梅,等.急骤起病伴胰酶增高的1 型糖尿病患者的临床和免疫学特征[J].中华医学杂志,2005,85:967-971.
[6] Chiou C C,Chung W H,Hung S I,et al.Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection[J].J Am Acad Dermatol,2006,54(2):S14-S17.
[7] 刘金玉,杨 郁.老年暴发性1型糖尿病合并心肌损伤1例报告[J].山东医学高等专科学校学报,2013,35(6):474-476.
[8] 罗 娜,佘敦敏.妊娠期暴发性1型糖尿病合并死胎1例[J].医学理论与实践,2014,27(22):3030-3031.
[9] 高建军,左 中,孙 纲,等.暴发性1型糖尿病并横纹肌溶解征肾功能变化[J].临床急诊杂志,2014,15(3):172-173.
[10] 金安林,谷 薇,赵红燕.暴发性1 型糖尿病合并急性肝损伤及急性粒细胞缺乏1例[J].内科理论与实践,2015,10(3):219-220.
[11] 赵向府,庄晓明,吴小娟.中国人暴发性1 型糖尿病2例病例临床特点总结及文献复习[J].首都医科大学学报,2013,34(3):466-469.
[12] Hanafusa T,Imagawa A.Fulminant type l diabetes a novel clinical entity requiring special attention by all medical practitioners[J].Nat ClinPractEndocrinolMatab,2007,3(1):36-45.
[13] Tanaka S, Kobayashi T,Momotsu T. A novel subtype of type 1 diabetes mellitus[J]. N Engl J Med, 2000,342(24):1835-1836.
[14] Takaike H. Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus[J]. Diabetes Res ClinPract,2004,64(5):27-32.
[15] Bronstein H D,Kantrowitz P A, Schaffner F.Marked Enlargement of the liver and transient ascites associated with the treatment of diabetic acidosis[J].N Engl J Med,1959,261:1314-1318.
[16] Shimizu I, Makino H, Imagawa A,et al. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy[J]. The Journal of clinical endocrinology and metabolism,2006,91(2):471-476.
[17] mutase Y,Imagawa A,hanafusa T,et al.Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy-a nationwide 5-year-study in Japan[J].Diabetologia,2007,50(3):531-537.
[18] Takaike H,Uchigata Y,Nakagami T,et al.Incidenceand development of diabetic microangiopathy of fulminant type 1 diabetes-comparison with non-fulminant type l diabetes[J].Intern Med,2010,49(12):1079-1083.
[19] Kim B Y. Jung C H. MokJ O,et al. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients[J].Actadiabetologica,2012,49(1):9-15.
[20] Panero F, Novelli G, Zucco C,et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients[J]. Diabetes Care,2009,32(1):301-305.

PDF(1018 KB)

Accesses

Citation

Detail

段落导航
相关文章

/